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Discussion
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• Hepatitis B virus remains indefinitely within nucleus         
of infected hepatocytes:
‣ viral DNA integrates itself into host DNA
‣ viral DNA is turned into covalently closed circular 
DNA (cccDNA) which functions as stable mini-
chromosomes
• Host machinery transcribes viral DNA into mRNA,      
which is used by HBV reverse transcriptase to generate 
progeny virions.
• Tenofovir AF, the first line therapy for chronic HBV,           
is a nucleotide analogue which inhibits reverse 
transcriptase to prevent viral replication.
• Tenofovir reduces disease burden, but does not  
target the viral DNA integrated into the host genome. 
Thus the virus is not eradicated. 
• Functional cure, where chronically infected patients can 
stop taking medication, is defined as the seroclearance of 
HBsAg. This occurs in only 1% of patients. 
• In our case, a negative HBeAg was confused for HBsAg 
and interpreted as having achieved seroclearance. 
• Discontinuation of Tenofovir in our patient led to 
enhanced viral replication which triggered the immune 
system to destroy infected hepatocytes, resulting in 
acute hepatitis, and ultimately need for liver transplant.
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A 51 year-old Vietnamese male with vertically transmitted 
chronic hepatitis B presents with symptoms of acute 
hepatitis for 2-3 weeks: jaundice, episodic fevers, diffuse 
abdominal discomfort, nausea, vomiting, and anorexia.  
He was previously treated with Tenofovir for a decade. 
2 months prior: Tenofovir stopped based on an 
undetectable HBV viral load and negative HBeAg.
1 week prior to admission: New transaminitis. 
HBV viral load of 796 million IU/mL. Tenofovir restarted.
Physical Exam
Vital: BP 151/91, HR 92, Temp 101.3, RR 18, 95% O2 RA
• Awake, alert, and comfortable
• Scleral icterus and jaundiced skin 
• Abdominal and neurological exam unremarkable 
Laboratory Tests and Imaging
• ALT 2,675, INR 1.6, total bilirubin 7.7
• CT: edematous liver suggesting hepatitis. 
No cirrhosis or liver masses.  
• Hepatitis A, C, D, CMV, EBV, HIV, blood alcohol, 
acetaminophen and salicylate level negative
• + HBsAg, - HBeAg, + Anti-HBc , + anti-HBe
• No cure for chronic hepatitis B currently
• On Tenofovir, an undetectable viral load indicates 
medication adherence, not hepatitis B eradication
• Therapy is most often continued indefinitely.  
Unlike Hepatitis C, it is rare (1%) to reach a functional 
cure of Hepatitis B (signified by the seroclearance of 
HBsAg) 
• Black box warning: Discontinuation of Tenofovir 
can result in acute hepatitis B reactivation leading to 
severe hepatic injury and even fulminant hepatic failure
• Initiating immunosuppression or chemotherapy 
can cause iatrogenic hepatitis B reactivation in 
undiagnosed patients. Be vigilant of the undiagnosed 
chronic hepatitis B carriers, most commonly seen in 
patients immigrating from countries with high HBV 
prevalence or in patients with high risk behaviors
350 million people worldwide live with chronic hepatitis B 
virus (HBV) infection, though only ~10% are aware of their 
diagnosis. Of those untreated, 25% are at risk for premature 
death from hepatocellular carcinoma and end stage liver 
disease. Treatment reduces disease burden, but a functional 
cure is rare.  Stopping treatment can provoke acute 
reactivation of chronic hepatitis B, defined as a rise in HBV 
DNA from baseline, and can result in severe hepatitis.  
Diagnosed with acute on chronic hepatitis B reactivation 
with severe hepatitis due to discontinuation of Tenofovir
First Hospitalization
• Tenofovir continued
• ALT, INR, and total bilirubin trended upwards     
without signs of fulminant hepatic failure
• Day 4: Lamivudine added to Tenofovir based on some 
studies improved survivability in acute reactivation 
Transplant evaluation initiated.
• Day 5: transaminitis and INR began to improve 
• Day 12: discharged despite increasing total bilirubin 
(takes days to normalize per transplant team)
Second Hospitalization (1 month later)
• Admitted with new ascites and melena
• Found to have liver cirrhosis by CT, portal 
hypertensive gastropathy, MELD score > 40, and 
increasing viral load compared to the previous week
• Developed fulminant hepatic failure 
• Underwent liver transplant with drastic improvement 
of liver synthetic function
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